Status:
UNKNOWN
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Immunocompromised Patients
Eligibility:
All Genders
18+ years
Brief Summary
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive r...
Eligibility Criteria
Inclusion
- Adult ≥ 18 years old
- Patients who received at least one administration of the following therapies: casirivimab-imdevimab, bamlanivimab-etesevimab, tixagevimab-cilgavimab, regdanvimab, sotrovimab or adintrevimab
Exclusion
- Patients opposed to the collection of their personal data
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT05439044
Start Date
March 1 2020
End Date
December 31 2022
Last Update
July 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital
Paris, Île-de-France Region, France, 75014